Guidelines for Managing Wheezing in 1-Year-Olds

Initial Assessment and Treatment Approach

The American Academy of Pediatrics and other medical societies suggest that wheezing in 1-year-olds is common, with approximately 34% of children experiencing at least one episode before age 3 years 1
Initial treatment should include short-acting beta-2 agonists (bronchodilators) delivered via metered-dose inhaler with a spacer and face mask for symptomatic relief, as recommended by the American Thoracic Society 2
Bronchodilator response may be variable in the first year of life but should still be attempted, according to the American College of Chest Physicians 2

Treatment Escalation for Persistent Symptoms

The American College of Allergy, Asthma, and Immunology recommends that for infants with persistent wheezing despite bronchodilator treatment, inhaled corticosteroids (ICS) are the preferred long-term control medication 3
ICS can be considered for infants who consistently require symptomatic treatment more than 2 days per week for a period exceeding 4 weeks, as suggested by the American Academy of Allergy, Asthma, and Immunology 3
The benefits of ICS outweigh concerns about potential risks of small, non-progressive reduction in growth velocity or other possible adverse effects, according to the American College of Allergy, Asthma, and Immunology 3

Delivery Devices and Medication Administration

Children under 4 years of age will generally have less difficulty with a face mask and either a nebulizer or a metered-dose inhaler (MDI) with a valved holding chamber (VHC), as recommended by the American Academy of Pediatrics 3
Every child given inhaled steroids from an MDI should use a large volume spacer to enhance deposition of medication in the lungs, according to the American Thoracic Society 2
FDA-approved long-term control medications for young children include Budesonide nebulizer solution, Fluticasone dry powder inhaler, and Montelukast, as approved by the FDA 3

Diagnostic Evaluation for Refractory Wheezing

An airway survey via flexible fiberoptic bronchoscopy should be considered to identify potential anatomic abnormalities, which are found in approximately 33% of cases, as suggested by the American Thoracic Society 1, 4
Bronchoalveolar lavage (BAL) may be useful to identify infectious or inflammatory causes, according to the American College of Chest Physicians 5
Video-fluoroscopic swallowing studies should be considered to evaluate for aspiration, which is identified in 10-15% of infants with respiratory symptoms, as recommended by the American Academy of Pediatrics 6, 7

Special Considerations

Breast feeding should be encouraged as it has a protective effect in relation to early life wheezing, according to the American Academy of Pediatrics 8
Most young children who wheeze with viral respiratory infections experience symptom remission by 6 years of age, possibly due to growing airway size, as suggested by the American College of Allergy, Asthma, and Immunology 3

Prognostic Factors

However, two-thirds of children with frequent wheezing AND a positive asthma predictive index are likely to have asthma throughout childhood, according to the American College of Allergy, Asthma, and Immunology 3
Increased frequency and severity of wheezing episodes in childhood are associated with recurrent wheeze into adulthood, as suggested by the American Thoracic Society 8

Common Pitfalls to Avoid

Overuse of nebulizers, which are expensive, time-consuming, and often inefficient compared to large volume spacer devices, should be avoided, as recommended by the American Thoracic Society 2
Failure to consider alternative diagnoses in infants with persistent symptoms, such as gastro-esophageal reflux, cystic fibrosis, and chronic lung disease of prematurity, should be avoided, according to the American College of Chest Physicians 2
Inadequate parent education about proper inhaler technique, medication administration, and recognition of worsening symptoms should be avoided, as suggested by the American Academy of Pediatrics 2

Management of Wheezing in Infants

Initial Treatment Approach

The American Academy of Allergy, Asthma, and Immunology recommends considering daily low-dose inhaled corticosteroids for infants meeting specific criteria, such as more than 3 wheezing episodes in the past year, parental history of asthma, or physician diagnosis of atopic dermatitis 9

Criteria for Initiating Long-Term Controller Therapy

Infants with severe exacerbations requiring urgent care or hospitalization should be considered for daily low-dose inhaled corticosteroids, as recommended by the American Academy of Allergy, Asthma, and Immunology 9
The American Thoracic Society suggests that alternative options for controller medications include cromolyn or leukotriene receptor antagonists, such as montelukast, for infants with persistent wheezing 9

Diagnostic Evaluation for Persistent or Refractory Wheezing

Approximately 33% of infants with persistent wheezing have identifiable anatomic abnormalities, including tracheomalacia, bronchomalacia, vascular rings, or airway compression, according to the American Thoracic Society 10
Flexible fiberoptic bronchoscopy with airway survey can identify these structural causes and guide management decisions, as recommended by the American Thoracic Society 10
90% of infants with tracheomalacia or bronchomalacia improve with conservative management alone, as stated by the American Thoracic Society 10
88-100% of infants with vascular rings or slings improve with surgical correction, according to the American Thoracic Society 10
40-60% of infants with persistent wheezing have positive bronchoalveolar lavage cultures indicating bacterial infection, as reported by the American Thoracic Society 11

Critical Pitfalls to Avoid

Beta-agonists may adversely affect airway dynamics in infants with tracheomalacia or bronchomalacia, so identification of these conditions is important, as noted by the American Thoracic Society 11

Alternative Diagnoses to Consider

The American Academy of Allergy, Asthma, and Immunology recommends evaluating for other causes of wheezing, such as cystic fibrosis, gastroesophageal reflux disease, foreign body aspiration, congenital heart disease, primary immunodeficiency, or vascular rings or slings, if standard asthma therapy fails 9

Management of Recurrent Wheezing in Infants (Evidence‑Based Recommendations)

Initial Pharmacologic Management

Short‑acting β₂‑agonist (salbutamol) delivered via metered‑dose inhaler with a spacer and face mask is the preferred first‑line therapy for symptomatic relief in a 12‑month‑old with recurrent wheezing. 12
Inhaled corticosteroid therapy (budesonide suspension for nebulization) should be considered when the infant has experienced ≥ 3 wheezing episodes in the past year and at least one high‑risk factor (parental asthma, atopic dermatitis, or severe episodes requiring urgent care). 12

Criteria for Initiating Long‑Term Inhaled Corticosteroid Therapy

Initiation requires > 3 episodes that each lasted > 1 day and affected sleep, plus at least one of the following risk factors:

Diagnostic Evaluation for Persistent Wheezing

Airway Anatomy (Bronchoscopy)

≈ 33 % of children with persistent wheezing have identifiable airway anatomical abnormalities on flexible fiber‑optic bronchoscopy. 13
The most common lesions are:
Minor procedural complications (transient hypoxemia) occur in 5‑10 % of cases. 13

Bronchoalveolar Lavage (BAL)

40‑60 % of children with persistent wheezing have positive BAL cultures, indicating bacterial infection. 12

Swallow Study (Videofluoroscopy)

Aspiration is detected in 10‑15 % of children presenting with respiratory symptoms, supporting evaluation for silent aspiration. [12][14]

Gastroesophageal Reflux Assessment

24‑hour esophageal pH monitoring shows gastroesophageal reflux in 47‑100 % of children with persistent wheezing. 15
> 83 % (most estimates 90‑100 %) of these children experience clinical improvement after appropriate medical or surgical reflux treatment. 15

Tests Not Recommended in Wheezing Evaluation

Empirical food avoidance in children without eczema is not advised. [12][14]
Upper gastrointestinal series radiography is not recommended for wheezing work‑up. [12][14]
Gastrointestinal scintigraphy is not recommended for wheezing assessment. [12][14]

Guideline Recommendations for Bronchodilator and Inhaled Corticosteroid Use in Infants with Persistent Wheezing

Bronchodilator Trial in Young Infants

The American Thoracic Society (ATS) advises that a therapeutic trial of short‑acting β₂‑agonists (e.g., albuterol) can be considered even in preterm infants, recognizing that their response may differ from that of full‑term infants. 16

Monitoring for Common Adverse Effects

When administering bronchodilators to infants, clinicians should watch for tachycardia, transient drops in oxygen saturation, and tremor as the most frequently reported side‑effects. 16

Inhaled Corticosteroid (ICS) Trial Criteria (Age‑Appropriate)

The ATS recommends that, for children old enough to receive FDA‑approved ICS (≥12 months), a 3‑month trial be instituted after establishing baseline symptom severity; the regimen should be reassessed at the end of this period to determine efficacy. 16, 17

Assessment of Treatment Response

Lack of clinical improvement after 2 weeks of bronchodilator therapy should raise the index of suspicion for alternative diagnoses and prompt consideration of diagnostic bronchoscopy. 16

Documentation and Follow‑Up

Prior to initiating or adjusting therapy, clinicians should record baseline wheeze frequency, severity, and any feeding‑related issues; this documentation guides subsequent management decisions and outcome evaluation. 16

Diagnostic Evaluation of Persistent Wheezing in Infants

Anatomic Abnormalities

Approximately one‑third (≈33%) of infants with persistent wheezing have identifiable anatomic abnormalities such as tracheomalacia, bronchomalacia, vascular rings, or airway compression. 18
Flexible fiberoptic bronchoscopy with a complete airway survey is recommended to detect structural causes; minor procedural complications (transient hypoxemia) occur in only 5–10% of procedures. 18

Aspiration Assessment

In infants whose wheezing does not improve with bronchodilators, a video‑fluoroscopic swallowing study should be performed to evaluate for aspiration. 18
Aspiration due to swallowing dysfunction is identified in 10–15% of infants presenting with respiratory symptoms. 18
More than 90% of infants with confirmed aspiration improve after feeding modifications (e.g., thickened feeds or temporary cessation of oral feeds with naso‑jejunal/gastrostomy feeding), with symptom resolution typically within 3–9 months. 18